Searchable abstracts of presentations at key conferences in oncology

oa0001p008 | (1) | PacRim7

Mechanisms underlying uncontrolled genome doubling in breast cancer

Lee Christine S , Rogers Samuel , Fernandez Kristine , Alexandrou Sarah , Deng Niantao , Sergio C Marcelo , Kulkarni Abhijit , Gugasyan Lucy , Musgrove Elizabeth A , Deans Andrew J , Burgess Andrew , Caldon C Elizabeth

Uncontrolled genome doubling is an underlying cause of cancer cell aneuploidy and genomic instability, but relatively few drivers have been identified for this process. Cyclin E1 and cyclin E2 are cell cycle regulators whose dysregulation in oncogenesis promotes both increased proliferation and genomic instability. Due to their roles in normal physiological endoreduplication of the genome for specialised cell types, we hypothesised that cyclin E1 and cyclin E2 may be drivers o...

oa0001p012 | (1) | PacRim7

Targeting AR in endocrine-resistant breast cancer

Chia KeeMing , Milioli Heloisa , Portman Neil , Laven-Law Geraldine , Coulson Rhiannon , Yong Aliza , Segara Davendra , Parker Andrew , Caldon Catherine E , Deng Niantao , Swarbrick Alexander , Tilley Wayne D , Hickey Theresa E , Lim Elgene

Introduction: Resistance to endocrine therapy is a major clinical problem in estrogen receptor positive (ER+) breast cancer. The androgen receptor (AR) is expressed in ~90% of all primary ER+ breast cancers and high expression of AR is associated with a better patient outcome in this tumours. However, uncertainty surrounding the role of AR in endocrine resistance is reflected in current clinical trials in which both AR agonists and antagonists are being investigated. Here, we ...